| 1/17 | Câncer Neves AF, Saraiva ACM, Julião JAS, Oliveira JDD, Oliveira Júnior, WP, Goulart LR. Androgen receptor: CAG repeat length and transcripitional levels related to prostate cancer. Applied Cancer Research, São Paulo: Tecmedd, v.28, n.4, p. 153-60, 2008. ISSN 1980-5578. Disponível em: http://accamargo.phlnet.com.br/applied/ACR200828p.153-60.pdf RECEPTOR; ANDROGEN; GENE EXPRESSION; PROSTATIC NEOPLASM; PROSTATIC HYPERPLASIA |
| 2/17 | Câncer Pellizzon ACA, Fogaroli RC, Silva MLG, Castro DG, Maia MC. Neoadjuvant androgen deprivation and long-term results for patients with intermediate- and high-risk prostate cancer treated with high-dose rate brachytherapy and external beam radiotherapy. Applied Cancer Research, São Paulo: Tecmedd, v.30, n.3, p. 306-12, 2010. ISSN 1980-5578. Disponível em: http://accamargo.phlnet.com.br/applied/ACR201030p.306-12.pdf |
| 3/17 | US=9 / Urologia Gelmann EP. Androgen receptor biology in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 61-70. ISBN 978-1-60327-831-7. ANDROGENO RECEPTOR DE BIOLOGIA; CANCER DE PROSTATA; RECEPTOR DE ANDROGENO; ANDROGENO; MUTACAO; COATIVADOR; BETA-CATENINA; P160 |
| 4/17 | US=9 / Urologia Shen HC, Taplin ME, Balk SP. Androgen receptor antagonists. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 71-81. ISBN 978-1-60327-831-7. ANTAGONISTAS DO RECEPTOR DE ANDROGENO; CANCER PROSTATA; ESTEROIDES; ESTEROIDE RECEPTOR; TESTOTERONA; DIIDROTESTOSTERONA; ANTAGONISTA; BICALUTAMIDA; FLUTAMIDA; NILUTAMIDA |
| 5/17 | US=9 / Urologia Friedlander TW, Ryan CJ. Adrenal androgen synthesis inhibitor therapies in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 91-100. ISBN 978-1-60327-831-7. SINTESE DE ANDROGENOS ADRENAIS; TERAPIAS INIBIDOR NA CASTRACAO-RESISTENTE; CANCER DE PROSTATA; TERAPIA HORMONAL SECUNDARIA; ANDROGENIOS ADRENAIS; ANDROGENO-INDEPENDENTES CANCER DE PROSTATA; CANCER DE PROSTATA HORMONIO REFRATARIO; FASE I; FASE I DE ENSAIOS CLINICOS; FARMACOCINETICA |
| 6/17 | US=9 / Urologia Sharifi N. Androgen deprivation therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 101-7. ISBN 978-1-60327-831-7. TERAPIA DE PRIVACAO DE ANDROGENO; TERAPIA DE PRIVACAO DE ANDROGENO; ANDROGENOS; CANCER DE PROSTATA; TESTOSTERONA |
| 7/17 | US=9 / Urologia Marques FZC, Reichardt JKV. Pharmacogenetics of the androgen metabolic pathway. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 109-21. ISBN 978-1-60327-831-7. FARMACOGENETICA; ANDROGENOS; DOENCA MULTIFATORIAL; CANCER DE PROSTATA; CANCER DE PROSTATA. TRATRAMENTO; CANCER DE PROSTATA. PREVENCAO; CANCER DE PROSTATA. FARMACOGENETICA |
| 8/17 | US=14 / Urologia Munarriz R, Traish A. Impact of androgen deprivation on male sexual function. In: Mulhall JP. Sexual function in the prostate cancer patient. New York: Humana Press, 2009. p. 163-75. ISBN 978-1-60327-554-5. IMPACTO DA PRIVACAO DE ANDROGENO; FUNCAO SEXUAL MASCULINA; ANDROGENOS; ABLACAO DO ANDROGENO; NOS; PDE; ADIPOCITOS; DISFUNCAO ERETIL |
| 9/17 | US=14 / Urologia Morgentaler A. Androgen supplementation in the prostate cancer patient. In: Mulhall JP. Sexual function in the prostate cancer patient. New York: Humana Press, 2009. p. 233-44. ISBN 978-1-60327-554-5. SUPLEMENTACAO DE ANDROGENOS; PACIENTE DE CANCER DE PROSTATA; TESTOSTERONA; ANDROGENO; CANCER DE PROSTATA; HIPOGONADISMO; TERAPIA DE REPOSICAO DE TESTOSTERONA; LIBIDO; DISFUNCAO ERETIL |
| 10/17 | US=96 / Biol/Mol Granata OM, Traina A, Ramirez S, Campisi I, Zarcone M, Amodio R, Polito LM, Carruba G. Dietary enterolactone affects androgen and estrogen levels in healthy postmenopausal women. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 232-6. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0. DIETA MEDITERRANEA; ENTEROLACTONA; INSULINA; TESTOSTERONA; ANDROSTERONA; ETIOCOLANOLONE; INTERVENCAO DIETETICA |
| 11/17 | US=96 / Biol/Mol Cocciadiferro L, Miceli V, Kang KS, Polito LM, Trosko JE, Carruba G. Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 257-62. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0. CELULAS-TRONCO DO CANCER; CANCER DE PROSTATA; MARCADORES DE CELULAS-TRONCO; DIFERENCIACAO MARCADORES DE CELULAS; METABOLISMO ANDROGENICO |
| 12/17 | US=10 / Urologia McLeod DG, Barqawi. Androgen deprivation for the treatment of prostate cancer: general principles. In: Kirby RS, Partin AW, Parsons JK, Feneley MR. Treatment methods for early and advanced prostate cancer. New York: Informa Healthcare, 2008. p. 279-84. ISBN 978-0415-458933-1. CANCER DE PROSTATA; ANDROGENIO; MECANISMO DE ACAO; REGULACAO DO CRESCIMENTO CELULAR |
| 13/17 | US=10 / Urologia Garnick MB, Motta C. Androgen deprivation therapy: the future. In: Kirby RS, Partin AW, Parsons JK, Feneley MR. Treatment methods for early and advanced prostate cancer. New York: Informa Healthcare, 2008. p. 295-306. ISBN 978-0415-458933-1. CANCER DE PROSTATA; TERAPIA HORMONAL; AGENTES HORMONAIS; TERAPIA DE PRIVACAO DE ANDROGENO |
| 14/17 | US=10 / Urologia Gleave M, Goldenberg SL. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. In: Kirby RS, Partin AW, Parsons JK, Feneley MR. Treatment methods for early and advanced prostate cancer. New York: Informa Healthcare, 2008. p. 307-15. ISBN 978-0415-458933-1. |
| 15/17 | US=23-A / Câncer Crook J. Locally advanced protate cancer biochemical recurrence after radiotherapy: use of cyclic androgen withdrawal therapy. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 565-77. ISBN 978-1-4020-8441-62. CANCER; CANCER DE PROSTATA; RECORRENCIA LOCALMENTE AVANCADO; BIOQUIMICA; RADIOTERAPIA; TERAPIA CICLICA; ANDROGENO |
| 16/17 | US=16 / Urologia Klocker H, Eder IE, Comuzzi B, Bartsch G, Culig Z. Biology and imaging: androgen receptor function in prostate cancer progression. In: Chung LWK, Isaacs WB, Simons JW. Prostate cancer: biology, genetics, and the new therapeutics. 2ª ed. New Jersey: Humana Press, 2007. p. 87-105. (Contemporary Cancer Research) ISBN 978-1-58829-696-2. BIOLOGIA; IMAGEM; FUNCAO DO RECEPTOR DE ANDROGENO; CANCER DE PROSTATA; AMPLIFICACAO; ABLACAO ANDROGENICA; RECEPTOR DE ANDROGENO; COATIVADORES; LIGANTE DE ATIVACAO INDEPENDENTE; MUTACOES |
| 17/17 | US=14 / Urologia Culig Z, Debes JD, Bartsch G, Tindall DJ. Prostate cancer: the role of the androgen receptor in the pathophysiology of prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM. Comprehensive textbook of genitourinary oncology. 3ª ed. Philadelphia: Lippincott Williams & Wilkins, 2006. p. 31-8. ISBN 978-0-7817-4984-0. CANCER DE PROSTATA; RECEPTOR ANDROGENO; CANCER DE PROSTATA. FISIOPATOLOGIA; REGULACAO DA TRANSCRICAO; PROTEINAS CO-REGULADORA; APOPTOSE; CICLO CELULAR; ANGIOGENESE; MUTACAO |